If this happens it is usually harder to treat. The average amount of time the men had denosumab was just over 19 months. And the men who had the dummy drug had it for 18 months. The trial team looked ...

The bone-modifying agents zoledronic acid, pamidronate, and denosumab have essential roles in supportive oncology for the treatment of hypercalcemia of malignancy and bone metastases, and prevention ...

Ulaanbaatar, May 23, 2025 /MONTSAME/. At the invitation of Speaker of the Illinois House of Representatives Emanuel Chris Welch, Honorary Consul of Mongolia in Chicago Battsetseg Tuvshintugs visited ...

Combining TPTD with anti-bone resorption drugs (e.g., bisphosphonates and denosumab) could reduce bone loss, yet existing randomised controlled trials (RCTs) remain inconclusive regarding their ...

Ulaanbaatar, May 20, 2025 /MONTSAME/. Deputy Prime Minister of Mongolia and Minister of Economy and Development Gantumur Luvsannyam received resident and non-resident Ambassadors Extraordinary and ...

This clinical trial against breast cancer, promoted by the Catalan Institute of Oncology (ICO), has analysed the potential anti-tumour role of denosumab, a drug already in use in the prevention of ...

This clinical trial against breast cancer has analyzed the potential anti-tumor role of denosumab, a drug already in use in the prevention of metastasis-related osteoporosis and bone lesions.

Denosumab, a drug commonly used to treat osteoporosis and prevent bone complications in cancer patients, is being investigated for a potential new application in breast cancer treatment. Early results ...

This clinical trial against breast cancer, promoted by the Catalan Institute of Oncology (ICO), has analysed the potential anti-tumour role of denosumab, a drug already in use in the prevention of ...